ABCB1 and neoplasm: This could be due to different methodologies or thresholds for calling amplifications, the tumor fraction >7% cut-off selecting for patients more likely to have ABCB1 amplification, or our study population reflecting a more heavily pre-treated cohort [34,35,36].